Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Les Laboratories Servier

Shanghai Institute of Pharmaceutical Industry

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Shanghai Dude Medical Science and Technology Co., Ltd.

Les Laboratoires Servier

Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.

Xingdong Cheng

Zhedong Yuan

Xiong Yu

Yu Huang

Xiquan Zhang

Aiming Zhang

Hanbin Shan

Hubo Wang

Xudong Jiang

Xufeng Cao

Peng Zhang

Xin Liu

Chunguang Xia

Hongjuan Pan

Xiaoping Chen

Wenliang Zhou

Ling Tong

Shan Chen

Rui Kong

Leilei Yang

Laifang Zhang

Yulei Yang

Ce Gao

Lang Chen

The present application relates to a method for preparing a cholic acid compound. Specifically, the method prepares a compound as shown in formula I, including subjecting a compound of formula 2 to an oxidization reaction to obtain a compound of formula 3; attaching a trimethylsilyl group to the compound of formula 3 to obtain a compound of formula 4; reacting the compound of formula 4 with acetaldehyde to obtain a compound of formula 5; subjecting the compound of formula 5 to a catalytic hydrogenation reaction to obtain a compound of formula 6; and converting a cyano group of the compound of formula 6 to a carboxyl group to give the compound of formula I. 

Method for preparing cholic acid compound

The present application relates to a method for preparing Ibutinib as shown by the following synthetic route and the intermediate compounds involved therein. 

Process for preparing ibrutinib

The present application discloses crystals of 2-acetoxy-5-(&#x3b1;-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrobromate, crystal compositions and pharmaceutical compositions comprising them and their use. The crystals of prasugrel hydrobromate of the present application possess excellent stability and solubility.

Crystals of prasugrel hydrobromate

The invention provides a new crystalline form of agomelatine, preparation and use thereof. The X-ray powder diffraction diagram of the agomelatine crystalline form shows main peaks at the diffraction angles 2&#x3b8; 11.13&#xb0;, 11.82&#xb0;, 17.49&#xb0;, 18.29&#xb0;, 19.48&#xb0;, 19.72&#xb0;, 20.50&#xb0;, 21.76&#xb0;, 22.54&#xb0;, 22.97&#xb0;, 24.56&#xb0;, 25.36&#xb0;, 27.16&#xb0; and 31.93&#xb0;. Said new crystalline form is characterized by high purity, stability and good reproducibility, and thus is advantageous for the pharmaceutical formulation. In addition, the stability and solubility of said crystalline form are also superior over the several existing crystalline forms.

Crystalline form VI of agomelatine, preparation method and application thereof

The present invention relates to a complex of agomelatine and to preparation thereof. The hydrogen halide complex of agomelatine obtained through the present method is more soluble, more stable, and of higher purity than agomelatine itself, making it more suitable to be used in pharmaceutical preparation. Using this method, product of high purity can be obtained through a simple process, without having to incur further complicated steps.

Agomelatine hydrohalide complex and preparation method thereof

Growing community of inventors

Shanghai, China

Xingdong Cheng